Factors prompting PSA-testing of asymptomatic men in a country with no guidelines: A national survey of general practitioners

BMC Family Practice

Volumn 10, Issue , 2009, Pages

  Drummond, Frances J ^a   Carsin, Anne Elie ^a   Sharp, Linda ^a   Comber, Harry ^a  

^a NATIONAL CANCER REGISTRY IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; BLOOD; CLINICAL PRACTICE; FEMALE; GENERAL PRACTICE; HUMAN; IRELAND; MALE; MIDDLE AGED; PRACTICE GUIDELINE; PROSTATE TUMOR; QUESTIONNAIRE;

ADULT; FAMILY PRACTICE; FEMALE; HUMANS; IRELAND; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUESTIONNAIRES;

EID: 60849125425     PISSN: None     EISSN: 14712296     Source Type: Journal    
DOI: 10.1186/1471-2296-10-3     Document Type: Article

References (57)

1. PSA screening among elderly men with limited life expectancies. LC Walter D Bertenthal K Lindquist BR Konety, JAMA 2006 296 2336 2442 10.1001/jama.296.19.2336 17105796
2. Evidence of prostate cancer screening in a UK region. A Gavin P McCarron RJ Middleton G Savage D Catney D O'Reilly PF Keane LJ Murray, BJU Int 2004 93 730 734 10.1111/j.1464-410X.2003.04716.x 15049981
3. Population-based prostate cancer trends in the United States: patterns of change in the era of prostate-specific antigen. RA Stephenson JL Stanford, World J Urol 1997 15 331 335 10.1007/BF01300179 9436281
4. Trends in prostate cancer epidemiology in the year 2000. A Trinchieri R Moretti, Arch Ital Urol Androl 2005 77 164 166 16372512
5. Screening for prostate cancer. D Ilic D O'Connor S Green T Wilt, Cochrane Database Syst Rev 2006 19 3 CD004720
6. Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute. JK Gohagan PC Prorok BS Kramer JE Cornett, J Urol 1994 152 1905 1909 7523735
7. The European Randomized Study of Screening for Prostate Cancer (ERSPC). FH Schröder CH Bangma, Br J Urol 1997 79 Suppl 1 68 71 9088276
8. Why is prostate cancer screening so common when the evidence is so uncertain? A system without negative feedback. DF Ransohoff M McNaughton Collins FJ Fowler, Am J Med 2002 113 663 667 10.1016/S0002-9343(02)01235-4 12505117
9. PSA testing and prostate cancer diagnosis in the Republic of Ireland. FJ Drummond L Sharp A-E Carsin S Deady H Comber, BJU Int 2007 100 Suppl 3 23
10. A study of PSA requests from general practitioners received by one Dublin Hospital. PG McGing, IMJ 1998 91 61 62 9617033
11. Major inter-laboratory variations in PSA testing practices: results from national surveys in Ireland in 2006 and 2007. F Drummond L Sharp H Comber, Ir J Med Sci 2008 177 317 323 10.1007/s11845-008-0216-1 18841439
12. PSA testing - weighing up the evidence. FJ Drummond H Comber, Forum; Clinical Focus 2007 7 15 18
13. "It's a maybe test": men's experiences of prostate specific antigen testing in primary care. R Evans AG Edwards G Elwyn E Watson R Grol J Brett J Austoker, Br J Gen Pract 2007 57 303 310 17394734
14. GP and patient predictors of PSA screening in Australian general practice. M Gattellari JM Young JE Ward, Fam Pract 2003 20 294 303 10.1093/fampra/cmg311 12738699
15. Knowledge, attitudes and experience associated with testing for prostate cancer: a comparison between male doctors and men in the community. P Livingston P Cohen M Frydenberg R Borland D Reading V Clarke D Hill, Intern Med J 2002 32 215 223 10.1046/j.1445-5994.2002.00211.x 12036219
16. Prostate-specific antigen testing: uncovering primary care influences. GJ Gormley D Catney JR McCall PM Reilly AT Gavin, BJU Int 2006 98 996 1000 10.1111/j.1464-410X.2006.06481.x 17034601
17. Factors influencing use of the prostate-specific antigen screening test in primary care. WP Moran SJ Cohen JS Preisser JL Wofford BJ Shelton MW McClatchey, Am J Manag Care 2000 6 315 324 10977432
18. Prostate cancer screening practices and beliefs. JD Voss JM Schectman, J Gen Intern Med 2001 16 831 837 11903762 10.1046/j.1525-1497.2001.10133.x
19. Prostate cancer screening-a physician survey in Missouri. DA Lawson EJ Simoes D Sharp T Murayi R Hagan RC Brownson J Wilkerson, J Community Health 1998 23 347 358 10.1023/A:1018745821888 9793832
20. Urological referral of asymptomatic men in general practice in England. J Melia P Coulson D Coleman S Moss, Br J Cancer 2008 98 1176 1181 10.1038/sj.bjc.6604291 18349841
21. The national Cancer Forum. A strategy for cancer control in Ireland. 2006 http://www.dohc.ie/publications/pdf/en-cancer-control-2006.pdf
22. Prostate Cancer Risk Management: NHS Cancer Screening Programmes. http://www.cancerscreening.nhs.uk/prostate/index.html.
23. Estimates of the cancer incidence and mortality in Europe in 2006. J Ferlay P Autier M Boniol M Heanue M Colombet P Boyle, Ann Oncol 2007 18 581 592 10.1093/annonc/mdl498 17287242
24. Cancer incidence in five continents. DM Parkin SL Whelan J Ferlay L Raymond J Young, Vol. VII Lyon (France): IARC 1997 143 316
25. Family history and the risk of prostate cancer. GD Steinberg BS Carter TH Beaty B Childs PC Walsh, Prostate 1990 17 337 347 10.1002/pros.2990170409 2251225
26. Dietary fat and prostate cancer: current status. LN Kolonel AM Nomura RV Cooney, J Natl Cancer Inst 1999 91 414 428 10.1093/jnci/91.5.414 10070940
27. Cancer incidence and mortality, 1973-1995: a report card for the U.S. PA Wingo LA Ries HM Rosenberg DS Miller BK Edwards, Cancer 1998 82 1197 1212 10.1002/(SICI)1097-0142(19980315)82:6〈1197::AID-CNCR26〉3.0.CO;2-0 9506368
28. Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma. K Mistry G Cable, J Am Board Fam Pract 2003 16 95 101 10.3122/jabfm.16.2.95 12665174
29. Screening for prostate cancer: a survey of New Zealand general practitioners. J Durham M Low D McLeod, N Z Med J 2003 116 U476 12835804
30. Questionnaire order significantly increased response to a postal survey sent to primary care physicians. FJ Drummond L Sharp A-E Carsin T Kelleher H Comber, J Clin Epidemiol 2008 61 177 185 10.1016/j.jclinepi.2007.04.012 18177791
31. Practitioner-level determinants of inappropriate prostate-specific antigen screening. BP Kerfoot EF Holmberg EV Lawler E Krupat PR Conlin, Arch Intern Med 2007 167 1367 1372 10.1001/archinte.167.13.1367 17620529
32. A simple method of sample size calculation for linear and logistic regression. FY Hsieh DA Bloch MD Larsen, Stat Med 1998 17 1623 1634 10.1002/(SICI)1097-0258(19980730)17:14〈1623::AID-SIM871〉3.0.CO;2-S 9699234
33. Structure of general practice in Ireland 1982-2005. T O'Dowd M O'Kelly F O'Kelly, http://www.medicine.tcd.ie/public-health-primary-care/research/reports/ GP-Structure.pdf
34. Rising incidence of prostate cancer in Scotland: increased risk or increased detection? DH Brewster LA Fraser V Harris RJ Black, BJU Int 2008 85 463 472 10.1046/j.1464-410x.2000.00487.x
35. Should mass screening for prostate cancer be introduced at a national level? World Health Organisation. Europe 2004 http://www.euro.who.int/Document/ E82958.pdf
36. Economic evaluation of prostate cancer screening with prostate-specific antigen. T Imamura H Yasunaga, Int J Urol 2008 15 285 288 10.1111/j.1442-2042. 2008.02013.x 18380812
37. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. R Etzioni DF Penson JM Legler D di Tommaso R Boer PH Gann EJ Feuer, J Natl Cancer Inst 2002 94 981 990 12096083
38. Anxiety associated with prostate cancer screening with special reference to men with a positive screening test (elevated PSA) - Results from a prospective, population-based, randomised study. S Carlsson G Aus C Wessman J Hugosson, Eur J Cancer 2007 43 2109 2116 10.1016/j.ejca.2007.06.002 17643983
39. Action Prostate Cancer. Irish Cancer Society, 2006 http://www.cancer.ie/ prostate
40. The National Cancer Forum: A Strategy for Cancer Control in Ireland. 2006 http://www.dohc.ie/publications/pdf/en-cancer-control-2006.pdf
41. Translating science to practice: community and academic perspectives. GA Colditz KM Emmons K Vishwanath JF Kerner, J Public Health Manag Pract 2008 14 144 149 18287920
42. Integrating research, practice, and policy: what we see depends on where we stand. JF Kerner, J Public Health Manag Pract 2008 14 193 198 18287927
43. The National Cancer Registry, Ireland. http://www.ncri.ie
44. Will men attribute fault to their GP for adverse effects arising from controversial screening tests? An Australian study using scenarios about PSA screening. M Gattellari JE Ward, J Med Screen 2004 11 165 169 10.1258/0969141042467386 15563771
45. Legal pitfalls in the diagnosis of prostate cancer. IB Dunn D Kirk, BJU Int 2000 86 304 307 10.1046/j.1464-410x.2000.00298.x 10930937
46. Avoidance of anticipated regret: the ordering of prostate-specific antigen tests. PC Sorum E Mullet J Shim S Bonnin-Scaon G Chasseigne J Cogneau, Med Decis Making 2004 24 149 159 10.1177/0272989X04263163 15090101
47. Why do primary care physicians in the United States and France order prostate-specific antigen tests for asymptomatic patients? PC Sorum J Shim G Chasseigne S Bonnin-Scaon J Cogneau E Mullet, Med Decis Making 23 301 313 10.1177/0272989X03256010 12926580
48. General practitioners' perceptions of medicolegal risk. Using case scenarios to assess the potential impact of prostate cancer screening guidelines. S Girgis JE Ward CJ Thomson, Med J Aust 1999 171 362 326 10590725
49. Survey of the rate of PSA testing in general practice. J Melia S Moss, Br J Cancer 2001 85 656 657 10.1054/bjoc.2001.1962 11531246
50. Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross-sectional study. J Melia S Moss L Johns Contributors in the participating laboratories, BJU Int 2004 94 51 56 10.1111/j.1464-4096.2004.04832.x 15217430
51. Screening for prostate cancer in the UK. Seems to be creeping in by the back door. JL Donovan SJ Frankel DE Neal FC Hamdy, BMJ 2001 323 763 764 11588064 10.1136/bmj.323.7316.763
52. PSA testing for prostate cancer: an online survey of the views and reported practice of General Practitioners in the UK. J Brett E Watson P Hewitson C Bukach A Edwards G Elwyn J Austoker, BMC Fam Pract 2005 6 24 15946386 10.1186/1471-2296-6-24
53. What are the ingredients for a successful evidence-based patient choice consultation?: A qualitative study. S Ford T Schofield T Hope, Soc Sci Med 2003 56 589 602 10.1016/S0277-9536(02)00056-4 12570976
54. Knowledge translation: closing the evidence-to-practice gap. ES Lang PC Wyer RB Haynes, Ann Emerg Med 2007 49 355 63 10.1016/j.annemergmed.2006.08.022 17084943
55. Research on changing practitioner and patient behavior. GJ Prince MV McDonald, Home Healthc Nurse 2007 25 89 93 10.1097/00004045-200702000-00008 17285035
56. An educational workshop on the early detection of prostate cancer-a before-after evaluation. SK Steginga C Pinnock PD Baade C Jackson A Green J Preston P Heathcote B McAvoy, Aust Fam Physician 2005 34 889 891 16217583
57. How underlying patient beliefs can affect physician-patient communication about prostate-specific antigen testing. MH Farrell MA Murphy CE Schneider, Eff Clin Pract 2002 5 120 129 12088291